Search

Your search keyword '"Gonsalves, Wilson I."' showing total 1,298 results

Search Constraints

Start Over You searched for: Author "Gonsalves, Wilson I." Remove constraint Author: "Gonsalves, Wilson I."
1,298 results on '"Gonsalves, Wilson I."'

Search Results

2. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms

3. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

4. Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing

6. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

7. Utility of flow cytometry screening before MRD testing in multiple myeloma

8. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

9. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

10. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

11. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design

12. First relapse in patients with multiple myeloma: Outcomes and predictors.

14. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia

15. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma

16. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

18. Prognostic restaging after treatment initiation in patients with AL amyloidosis

22. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia

23. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation

26. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

27. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation

28. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant

29. Revisiting complete response in light chain amyloidosis

30. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

34. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy

35. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

39. Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ‘graft versus host’-like syndrome and poor outcomes

40. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma

42. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma

43. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis

44. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse

45. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients

49. Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis

50. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Catalog

Books, media, physical & digital resources